Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 999 - 1009
Section Un siècle d’histoire
DOI https://doi.org/10.1051/medsci/20092512999
Publié en ligne 15 décembre 2009
  1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7. [Google Scholar]
  2. Von Behring E, Kitasato S. Über das Zustandekommen der Diphterie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 1890; 49 : 1113–45. [Google Scholar]
  3. Roux E, Martin L, Chaillou A. Trois cents cas de diphtérie traités par le sérum antidiphtérique. Ann Inst Pasteur 1894; 8 : 640–61. [Google Scholar]
  4. Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003; 41 : 541–57. [Google Scholar]
  5. Rénon L. Deux cas de tétanos traités par des injections de sang antitoxique (méthode de MM. Behring et Kitasato). Ann Inst Pasteur 1892; 6 : 233–41. [Google Scholar]
  6. Roux E, Vaillard L. Contribution à l’étude du tétanos ; prévention et traitement par le sérum antitoxique. Ann Inst Pasteur 1893; 7 : 65–140. [Google Scholar]
  7. Smolens J, Vogt A, Crawford M, Stokes JJ. The persistence in the human circulation of horse and human tetanus antitoxins. J Pediatr 1961; 59 : 899–902. [Google Scholar]
  8. Rubbo SD, Suri JC. Passive immunization against tetanus with human immune globulin. Br Med J 1962; 2 : 79–81. [Google Scholar]
  9. Gibaldi M. Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock. Pharmacotherapy 1993; 13 : 302–8. [Google Scholar]
  10. Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69 : 12–8. [Google Scholar]
  11. Maynard JA, Maassen CB, Leppla SH, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002; 20 : 597–601. [Google Scholar]
  12. Nowakowski A, Wang C, Powers D, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002; 99 : 11346–50. [Google Scholar]
  13. Héricourt J, Richet C. Technique des procédés pour obtenir du sérum pur de chien et innocuité des injections de ce liquide chez l’homme. CR Soc Biol 1891; 3 : 33–5. [Google Scholar]
  14. Héricourt J, Langlois P, Saint-Hilaire A. Effet thérapeutique des injections de sérum de chien (hémocyne) chez l’homme, dans le cours de la tuberculose. CR Soc Biol 1891; 3 : 45–53. [Google Scholar]
  15. Legrain E. Histoire d’une épidémie de typhus exanthématique ; essais de sérothérapie ; action bienfaisante des injections sous-cutanées de sérum de typhiques convalescents. Gaz Hôp 1895; 68 : 766–8. [Google Scholar]
  16. Debré R. La séroprophylaxie de la rougeole et ses applications pratiques. Monde Med 1925; 35 : 822–35. [Google Scholar]
  17. Metchnikoff E. Études sur la résorption des cellules. Ann Inst Pasteur 1899; 13 : 737–69. [Google Scholar]
  18. Brent L. A history of transplantation immunology. San Diego : Academic Press, 1997 : 247–65 et 319–20. [Google Scholar]
  19. Finn R, Clarke CA, Donohoe WT, et al. Experimental studies on the prevention of Rh haemolytic disease. Br Med J 1961; 1 : 1486–90. [Google Scholar]
  20. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93 : 99–111. [Google Scholar]
  21. Béliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141 : 109–19. [Google Scholar]
  22. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32 : 535–9. [Google Scholar]
  23. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002; 19 : S3–9. [Google Scholar]
  24. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69 : 584–91. [Google Scholar]
  25. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 : 435–45. [Google Scholar]
  26. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104 : 2635–42. [Google Scholar]
  27. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 9 : 754–8. [Google Scholar]
  28. Nopora A, Preiss S, Nicolini V, et al. Contribution of enhanced ADCC to superior in vivo efficacy of a novel type II humanized, third generation CD20 antibody (GA101) in NHL xenograft models. AACR Meeting Abstracts 2008 : 3991. [Google Scholar]
  29. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140 : 635–43. [Google Scholar]
  30. Héricourt J, Richet C. De la transfusion péritonéale, et de l’immunité qu’elle confère. CR Acad Sci 1888; 107 : 748–50. [Google Scholar]
  31. Héricourt J, Richet C. Traitement d’un cas de sarcome par la sérothérapie. CR Acad Sci 1895; 120 : 948–50. [Google Scholar]
  32. Héricourt J, Richet C. De la sérothérapie dans le traitement du cancer. CR Acad Sci 1895; 121 : 567–9. [Google Scholar]
  33. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306 : 517–22. [Google Scholar]
  34. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89 : 4285–9. [Google Scholar]
  35. Soulillou JP, Peyronnet P, Le Mauff B, et al. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet 1987; 1 :1339–42. [Google Scholar]
  36. Gold HK, Gimple LW, Yasuda T, et al. Pharmacodynamic study of F(ab’)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86 : 651–9. [Google Scholar]
  37. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44 : 1002–7. [Google Scholar]
  38. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 : 3992–5. [Google Scholar]
  39. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27 : 1122–9. [Google Scholar]
  40. Perez N, Le Deist F, Chatenoud L, et al. In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects. Bone Marrow Transplant 1989; 4 : 379–84. [Google Scholar]
  41. Antonyuk SV, Trevitt CR, Strange RW, et al. Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci USA 2009; 106 : 2554–8. [Google Scholar]
  42. Levites Y, Smithson LA, Price RW, et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse models. FASEB J 2006; 20 : 2576–8. [Google Scholar]
  43. Yonehara S. Effects of anti-Fas antibodies on lymphocytes and other organs: preparation of original and new monoclonal antibodies and amelioration of systemic autoimmune disease. Int Rev Immunol 1999;18 : 329–45. [Google Scholar]
  44. Chatenoud L, Baudrihaye MF, Kreis H, et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12 : 979–82. [Google Scholar]
  45. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7 : 622–32. [Google Scholar]
  46. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58 : 823–30. [Google Scholar]
  47. Hernández AM, Toledo D, Martínez D, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181 : 6625–34. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.